Mologic has earned a CE mark approval for PERiPLEX®, a rapid point-of-care test for the detection of infection in patients on Peritoneal Dialysis (PD).
PD is widely considered to be the preferred method of managing chronic kidney disease and end stage renal disease because unlike haemodialysis, which is performed at a dialysis centre, hospital or at home, requiring patients to be connected to a dialysis machine for hours at a time, patients on PD may be treated while they go about their daily activities, or at night while they sleep.
PD patients have a catheter surgically placed in the chest or abdomen ahead of treatment. Patients with catheters in their abdomen are more prone to peritonitis, a serious infection requiring quick antibiotic treatment to prevent problems such as damage to the peritoneal membrane. Current methods can take longer than 24 hours to diagnose infection, however Mologic’s Periplex test, which detects two critical biomarkers of infection in PD waste fluid, returns results in 10 minutes.
Mologic CEO Mark Davis commented: “PERiPLEX is the first of a pipeline of products from Mologic to receive CE mark approval. We are developing similar diagnostic tests for a range of disease areas, including sepsis, urinary tract infections and chronic obstructive pulmonary disease (COPD). Each of these tests use lateral flow immunoassay technology to detect a host inflammatory response, for rapid, point-of-care diagnosis and, importantly, to enable earlier treatment for patients.
Read the full article here